Bristol bumps Lynch, recruits Novartis vet for post-merger team by Arlene Weintraub Wednesday, June 5, 2019 Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Celgene CEO Alles to bag $28M if he departs after BMS merger by Arlene Weintraub Wednesday, February 27, 2019 Celgene's recently adopted change-in-control severance system could pay off big time for Celgene CEO Mark Alles and three other top executives.
Celgene exec shakeup continues as J&J vet Elkins signs on as CFO by Arlene Weintraub Friday, June 1, 2018 Embattled Celgene already bid goodbye to its COO and business development guru, and now it's moving up its executive ranks to make more changes.
